New treatment for Ecstasy-related hyperthermia

Internal Medicine Journal

Volumn 33, Issue 12, 2003, Pages 555-556

  Blessing, W W ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; COCAINE; DOPAMINE 3 RECEPTOR; OLANZAPINE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR;

AGRANULOCYTOSIS; BODY TEMPERATURE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG SOLUBILITY; HUMAN; HYPERTHERMIA; MEDICAL ETHICS; MENTAL DISEASE; NONHUMAN; NOTE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SEROTONINERGIC SYSTEM; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SKIN NERVE; SYMPATHETIC INNERVATION; TABLET FORMULATION; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DISEASE MODELS, ANIMAL; FEVER; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SEROTONIN ANTAGONISTS;

EID: 1642512333     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2003.00493.x     Document Type: Note

References (2)

1. Blessing WW, Seaman B, Pedersen NP, Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4 methylenedioxymethamphetamine (Ecstasy) in rabbits and rats. J Neurosci 2003; 23: 6385-91.
2. Bodenham AR & Mallick A. New Dimensions in toxicology: hyperthermic syndrome following amphetamine derivatives. Intensive Care Med 1996; 22: 622-4.